150 related articles for article (PubMed ID: 31277120)
1. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles.
Devalet B; Wannez A; Bailly N; Alpan L; Gheldof D; Douxfils J; Bihin B; Chatelain B; Dogné JM; Chatelain C; Mullier F
Medicine (Baltimore); 2019 Jul; 98(27):e16164. PubMed ID: 31277120
[TBL] [Abstract][Full Text] [Related]
2. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study.
Wannez A; Devalet B; Bouvy C; Laloy J; Bihin B; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Res; 2017 Aug; 156():142-148. PubMed ID: 28646725
[TBL] [Abstract][Full Text] [Related]
3. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
[TBL] [Abstract][Full Text] [Related]
5. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
Macrae FL; Peacock-Young B; Bowman P; Baker SR; Quested S; Linton E; Hillmen P; Griffin M; Munir T; Payne D; McKinley C; Clarke D; Newton DJ; Hill A; Ariëns RAS
Am J Hematol; 2020 Aug; 95(8):944-952. PubMed ID: 32311169
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
[TBL] [Abstract][Full Text] [Related]
8. Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.
Alashkar F; Weber SN; Vance C; Herich-Terhürne D; Dührsen U; Lammert F; Röth A
Eur J Haematol; 2017 Oct; 99(4):350-356. PubMed ID: 28692147
[TBL] [Abstract][Full Text] [Related]
9. Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment.
Arcavi M; Ceballo F; Caracciolo MB; Lazarowski A
Int J Lab Hematol; 2020 Jun; 42(3):335-340. PubMed ID: 32202389
[TBL] [Abstract][Full Text] [Related]
10. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
11. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
Nishimura JI
Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
13. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
14. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
[TBL] [Abstract][Full Text] [Related]
15. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
17. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
18. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
Plessier A; Esposito-Farèse M; Baiges A; Shukla A; Garcia Pagan JC; De Raucourt E; Ollivier-Hourmand I; Cervoni JP; De Ledinghen V; Tazi Z; Nousbaum JB; Bun R; Bureau C; Silvain C; Tournilhac O; Gerfaud-Valentin M; Durand F; Goria O; Tellez L; Albillos A; Gioia S; Riggio O; De Gottardi A; Payance A; Rautou PE; Terriou L; Charbonnier A; Elkrief L; de la Tour RP; Valla DC; Gault N; de Fontbrune FS
Am J Hematol; 2022 Apr; 97(4):431-439. PubMed ID: 35049058
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
Miyasaka N; Miura O; Kawaguchi T; Arima N; Morishita E; Usuki K; Morita Y; Nishiwaki K; Ninomiya H; Gotoh A; Imashuku S; Urabe A; Shichishima T; Nishimura J; Kanakura Y
Int J Hematol; 2016 Jun; 103(6):703-12. PubMed ID: 26857155
[TBL] [Abstract][Full Text] [Related]
20. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
